This program is supported by an independent educational grant from Pfizer. This education program is available to healthcare professionals globally.
Join prostate cancer experts Dr. Michael Schweizer and Dr. Emmanuel Antonarakis for this accredited, interactive teaching session focused on the latest updates for 2026 in overcoming treatment resistance and optimizing therapeutic pathways in metastatic castration-resistant prostate cancer (mCRPC). Through real-world cases and expert-led discussion, faculty will translate emerging evidence into practical strategies to support sequencing decisions after AR pathway inhibitor (ARPI) progression. This program also includes an interview with a patient advocate from Zero Prostate Cancer, Darrell Wilson.
Accreditation: 1 AMA PRA Category 1 Credits™
Session Overview
Overcoming Resistance and Optimizing Pathways
This case-based session explores how evolving insights into resistance biology can inform more precise, personalized treatment decisions in mCRPC. Faculty will guide learners through common clinical scenarios encountered after ARPI progression, highlighting how biomarkers, emerging mechanisms, and novel non-chemotherapy approaches may shape next steps in care.
- Review emerging insights into resistance biology beyond DNA repair, including lineage plasticity, AR co-activation, and epigenetic dysregulation, and how these concepts are influencing contemporary mCRPC thinking
- Discuss the growing translational rationale for targeting epigenetic pathways such as EZH2, including current evidence gaps and implications for future practice
- Compare novel non-chemotherapy approaches—including radioligand therapies, antibody–drug conjugates, and immunotherapies—and where these modalities may fit within emerging treatment paradigms
- Engage in expert-led Q&A, interactive polling, and a patient voice vignette highlighting real-world decision points, uncertainty, and practice variation
Who Should Watch
This program is designed for healthcare professionals globally involved in the diagnosis, treatment selection, and ongoing management of patients with mCRPC, including:
- Medical and radiation oncologists
- Urologists
- Oncology nurses and nurse practitioners
- Physician assistants
- Pharmacists
- Others involved in prostate cancer care
Presented by
Michael Schweizer, M.D.
Medical oncologist specializing in genitourinary cancers with expertise in advanced prostate cancer, resistance mechanisms, and clinical trials evaluating novel therapeutic strategies in mCRPC.
Emmanuel Antonarakis, M.D.
Internationally recognized prostate cancer expert and clinician-scientist with extensive experience in resistance biology, biomarker-driven treatment selection, and translational research guiding precision approaches in mCRPC.
Darrell Wilson
A patient advocate representing Zero Prostate Cancer.
Continuing Education Information
Commercial support: This activity received monetary support through an independent education grant from Pfizer.
This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.
Disclosures
Emmanuel Antonarakis, MD, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisory Board/Consultant for Abeona Therapeutics, AstraZeneca, Bayer, DAVA Oncology, EcoR1, Janssen, Johnson & Johnson, Lilly, Merck, MJH Life Sciences, Pfizer, Tango Therapeutics, Tempus, The Medical Educator Consortium, z-Alpha. Grant/Research Support from Bayer, Bristol-Myers Squibb, Clovis, MacroGenics, Merck, Novartis, Orion, Seagen. Honoraria for Binaytara, ClearView, Curium, Fred Hutch Cancer Center, Healthcare Partners, Lilly, Merck. These disclosures are provided in accordance with ACCME standards to ensure transparency and uphold the integrity of continuing education. Dr. Antonarakis does not intend to reference any unlabeled or unapproved uses of products during the presentation.
Michael Schweizer, MD, has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Advisory Board for Daiichi Sankyo, Fibrogen, J&J, Pfizer, Consultant for Bayer, K36 Therapeutics, Grant/Research Support from Ambrx, AstraZeneca, BMS, Epigenetix, J&J, Lightspeed, Merck, Novartis, Oric Pharmaceuticals, Pfizer, Xencor, Zenith Epigenetics.These disclosures are provided in accordance with ACCME standards to ensure transparency and uphold the integrity of continuing education. Dr. Schweizer does intend to reference unlabeled or unapproved uses of products during the presentation.
Darrell Wilson has disclosed financial interests or relationships within the past 24 months with the following ineligible companies: Patient perspective involvement for Sandoz, Novartis, Pfizer.
AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.
Mitigation of Relevant Financial Relationships
AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible companies. Relevant financial relationships were mitigated by the peer review of content by non-conflicted reviewers prior to the commencement of the program.
Activity Accreditation for Health Professions
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this live activity for a maximum of 1_AMA PRA Category 1 Credits™_. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this live activity for a maximum of 1_AMA PRA Category 1 Credits™_. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this live activity for a maximum of 1_AMA PRA Category 1 Credits™_. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.
Nurses & Other Professionals
All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
System Requirements
Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.
Unapproved and/or off-label use disclosure
AffinityCE/MedAll requires CE faculty to disclose to the participants:
- When products or procedures being discussed are off-label, unlabelled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
- Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
CME Inquiries
For all CME policy-related inquiries, please contact us at ce@affinityced.com.
Participation Costs
There is no cost to participate in this program.
Disclaimer
This activity is intended for educational purposes only and does not establish a standard of care or replace clinical judgment. Any therapeutic or diagnostic strategies discussed must be evaluated in the context of each patient’s clinical circumstances, risks, and current evidence.
Learners should consult authoritative clinical guidelines and approved product information when considering treatment decisions.
All materials are used with permission. The views expressed are those of the faculty and do not necessarily reflect those of the accredited providers, MedAll, or any supporters.
Content is accurate as of the date of release.
Launch and Expiration Date: 23 February 2026 – 23 February 2026
Estimated time to complete this activity: 60 minutes